Syndax Pharmaceuticals
SNDX
136 hedge funds and large institutions have $948M invested in Syndax Pharmaceuticals in 2022 Q1 according to their latest regulatory filings, with 27 funds opening new positions, 53 increasing their positions, 31 reducing their positions, and 23 closing their positions.
7,305% more call options, than puts
Call options by funds: $1.55M | Put options by funds: $21K
71% more repeat investments, than reductions
Existing positions increased: 53 | Existing positions reduced: 31
17% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 23
3% more funds holding
Funds holding: 132 → 136 (+4)
0.59% less ownership
Funds ownership: 99.77% → 99.19% (-0.59%)
17% less capital invested
Capital invested by funds: $1.15B → $948M (-$199M)
33% less funds holding in top 10
Funds holding in top 10: 6 → 4 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
KCM
Kynam Capital Management
Princeton,
New Jersey
|
+$16.4M |
| 2 |
Morgan Stanley
New York
|
+$7.08M |
| 3 |
Millennium Management
New York
|
+$6.86M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
+$4.97M |
| 5 |
PBA
Paradigm Biocapital Advisors
New York
|
+$4.18M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FM
Frazier Management
Seattle,
Washington
|
-$60.7M |
| 2 |
Barclays
London,
United Kingdom
|
-$11.8M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$6.79M |
| 4 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
-$6.22M |
| 5 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$3.94M |
SNDX Hedge Fund Activity: Q1 2022 in Review
136 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Syndax Pharmaceuticals (SNDX) for Q1 2022, worth a combined $948M — down 17% from $1.15B a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SNDX positions and 23 closed out — a net gain of 4 holders — while 53 added to existing stakes and 31 trimmed.
The largest buyer was Kynam Capital Management, adding an estimated $16.4M. The largest seller was Frazier Management, exiting entirely with an estimated $60.7M sold.
- 136 institutional investors held Syndax Pharmaceuticals (SNDX) as of Q1 2022, up from 132 in Q4 2021.
- Funds reported $948M of Syndax Pharmaceuticals stock for Q1 2022, down 17% quarter-over-quarter.
- 27 funds opened new Syndax Pharmaceuticals positions in Q1 2022 and 23 closed out, a net change of +4 holders.
- The largest Syndax Pharmaceuticals buyer in Q1 2022 was Kynam Capital Management, an estimated $16.4M added.
- The largest Syndax Pharmaceuticals seller in Q1 2022 was Frazier Management, an estimated $60.7M sold.
Based on aggregated 13F filings for Q1 2022.